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Since the 2000s, we have known that female genital schistosomiasis (FGS) is likely the most
neglected gynecologic condition and HIV/AIDS cofactor across sub-Saharan Africa. To date,
the global health and HIV/AIDS communities have not used the opportunity to prevent new
HIV/AIDS infections through highly cost-effective schistosomiasis control and elimination in
Africa. But recently, this situation may be shifting toward the better.
FGS is caused by the terminal-spine parasite eggs released from the female Schistosoma hae-
matobium parasite. When the eggs are deposited in the tissues of the cervix and lower female
genital tract, the presence of the eggs, combined with host inflammation and increased vascu-
larity in the cervicovaginal mucosa, produces typical intravaginal lesions that result in genital
itching and pain, bleeding, and dyspareunia [1–4]. In addition, eggs deposited in the uterus
and fallopian tubes can result in infertility [2, 3]. There are also associated and profound men-
tal health effects from social stigma, such as depression and marital discord [1, 2], and the con-
dition frequently gets confounded with sexually transmitted infections.
FGS is also incredibly common. Approximately two-thirds of Africa’s 200 million schisto-
somiasis cases are caused by S. haematobium, and it is estimated that up to three-quarters of
girls and women with S. haematobium infection have FGS [5]. On this basis, FGS may repre-
sent sub-Saharan Africa’s most common gynecologic condition, affecting tens of millions of
girls and women [6]. Yet, FGS in not mentioned in most medical textbooks, nor in the lay
press, which has further compounded the very low awareness about the condition.
As if this information were not bad enough, several large epidemiological studies show that
FGS is responsible for up to a three- to four-fold increase in horizontal transmission of HIV/
AIDS [2, 7, 8], whereas a regression analysis of prevalence of S. haematobium infection and
HIV in sub-Saharan African countries found that each S. haematobium infection per 100 indi-
viduals resulted in a 3% relative increase in HIV prevalence [9].
Given the high prevalence and incidence of FGS and its strong geographic overlap with
HIV/AIDS in countries such as Malawi, Mozambique, South Africa, Tanzania, Zimbabwe,
and elsewhere, it stands to reason that FGS would be identified as a leading HIV/AIDS cofac-
tor in Africa, and that mass drug administration (MDA) with the antiparasitic drug, prazi-
quantel, would represent an important strategy for HIV/AIDS prevention. Indeed, two
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transmission modeling studies found that in rural Zimbabwe, praziquantel MDA is a highly
cost-effective means of reducing HIV/AIDS transmission [10, 11]. Now that praziquantel is
being donated free of charge to sub-Saharan Africa by the German-based Merck KgaA for
treatment of school-age children [12], praziquantel MDA may represent one of the most cost-
effective means of contributing to HIV/AIDS prevention in Africa.
From the beginning of efforts to integrate MDA with praziquantel with other neglected
tropical diseases (NTDs) amenable to MDA, there have been calls to link these activities with
HIV/AIDS prevention efforts in Africa. Such efforts could include combining praziquantel
MDA with antiretroviral treatment and pre-exposure prophylaxis (PrEP) programs, as well as
other measures [13–15]. Indeed, multiple (and peer-reviewed) scientific papers have been
written on this subject [13–21], but they have largely appealed to the community of scientists
and public health experts committed to NTDs. Therefore, although “preaching to the con-
verted” has helped to unify the NTDs community, it has (so far) done little to stimulate the
global HIV/AIDS community toward accepting the importance of praziquantel MDA as a key
component of strategies to prevent new infections of HIV/AIDS. For that reason, there was at
best only modest progress on this front from the major global organizations committed to
HIV/AIDS prevention, including UNAIDS, the One Campaign, the Clinton Foundation, the
US President’s Emergency Plan for AIDS Relief (PEPFAR), and the Global Fund to Fight
AIDS, Tuberculosis, and Malaria (GFATM). However, this situation may soon improve.
Over the last five years, the case to incorporate praziquantel MDA into HIV/AIDS treat-
ment programs has advanced even further due to new and important developments. They
include the successful testing of a new prodispersable formulation of praziquantel suitable for
use in treating young (preschool age) children to prevent the onset of the genital lesions lead-
ing to FGS, together with expanded treatment programs for young children and pregnant
women [20, 22–24], improved FGS diagnostic technologies and algorithms [25–31], and
expanded surveillance for FGS [23, 24]. Also, there are now better basic science tools available,
including a new mouse model and the applications of genomics, proteomics, metabolomics,
and gene editing technologies and an expanded array of immunological reagents, to under-
stand the pathogenesis of FGS [32–35]. Such studies could provide fundamental information
on how FGS damages host tissues and leads to increased susceptibility to HIV/AIDS. Addi-
tionally, efforts have been made to develop FGS vaccines alongside HIV/AIDS vaccines, with
several schistosomiasis vaccines now in clinical testing [36]. There are also efforts in place to
improve local advocacy and health education around FGS [37].
Through such developments, could anti-schistosomal control efforts, including MDA,
become essential elements in the HIV/AIDS prevention programmes? So far the uptake has
been extremely slow. But now, both the Department of Control of NTDs at the World Health
Organization, together with UNAIDS, are working towards joint programs of policy and
advocacy to create some paradigm-changing shifts. Similarly, there is an urgency to integrate
schistosomiasis treatments into broader health systems for women’s health, including ante-
natal programs, HIV/AIDS prevention programs, and cervical cancer screening clinics [23,
24, 38].
Realizing that declines in new HIV/AIDS infections remain too slow, especially in younger
women aged 15–24 years who are twice as likely to be living with HIV than men [39]—in 25
countries, of which 18 in sub-Saharan Africa—UNAIDS launched its Prevention 2020 Road
Map [40] calling for innovative combination prevention packages, in addition to HIV screen-
ing, counseling, and treatment programs. Since 2017, several parallel sessions have taken place
at international AIDS and Women’s conferences—including the 22nd International AIDS
Conference held in Amsterdam, the Netherlands in 2018—calling for a more holistic approach
to women’s health and HIV. More specifically, the integration of services for HIV, FGS,
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Human Papilloma Virus (HPV), and cervical cancer prevention and control is called for, to
improve reproductive health services and save women’s lives [41–42]. In early 2019, UNAIDS
and WHO are scheduled to issue a joint Advocacy Brief on FGS and HIV.
In the meantime, the major organizations focused on integrated control and elimination of
NTDs, including the WHO, continue to expand praziquantel MDA efforts in concert with the
Merck KGaA donations. According to the WHO, despite making impressive gains in 2017, we
are still falling short of meeting the minimum target of treating at least 75% of the African chil-
dren who require regular and periodic administration of praziquantel [43]. These efforts could
largely be accelerated (sustainably) were countries allowed to include them in all-out HIV/
AIDS prevention and care programs supported by PEPFAR and GFATM. Incorporation with
major AIDS organizations might also allow an expansion of efforts in Africa to mobilize com-
munities, create demand for holistic female reproductive health services, and address the social
stigma and mental health issues of FGS, which, for now, largely remain ignored except for a
handful of one-off efforts. Additionally, medical training materials must be updated to include
FGS. The clinical research community—including primary health care nurses in remote areas,
pediatricians, and gynecologists—should engage in the development of appropriate treatment
protocols for patients who develop FGS.
The overall neglect of the serious consequences of FGS represents an affront to the girls
and women of Africa and their families in poverty-stricken communities. We have the sup-
porting data and tools to both prevent FGS and reduce HIV/AIDS transmission in Africa. We
shouldn’t continue to leave this extraordinary opportunity on the table, unused.
References
1. Kjetland EF, Hegertun IE, Baay MF, Onsrud M, Ndhlovu PD, Taylor M (2014) Genital schistosomiasis
and its unacknowledged role on HIV transmission in the STD intervention studies. Int J STD AIDS. 2014
Sep; 25(10):705–15. https://doi.org/10.1177/0956462414523743 PMID: 24621458
2. Downs JA, Mguta C, Kaatano M, Mitchell B, Bang H, Simplice H, et al. (2011) Urogenital schistosomia-
sis in women of reproductive age in Tanzania’s Lake Victoria Region. Am J Trop Med Hyg 84(3): 364–
9. https://doi.org/10.4269/ajtmh.2011.10-0585 PMID: 21363971
3. Woodall PA, Kramer MR (2018) Schistosomiasis and infertility in East Africa. Am J Trop Med Hyg
98(4): 1137–44. https://doi.org/10.4269/ajtmh.17-0280 PMID: 29313478
4. Jourdan PM, Roald B, Poggensee G, Gundersen SG, Kjetland EF (2011) Increased vascularity in cervi-
covaginal mucosa with Schistosoma haematobium infection. PLoS Negl Trop Dis 5(6): e1170 https://
doi.org/10.1371/journal.pntd.0001170 PMID: 21666790
5. Kjetland EF, Kurewa EN, Ndhiovu PD, Midzi N, Guanzura L, Mason PR, et al. (2008) Female genital
schistosomiasis—a differential diagnosis to sexually transmitted disease: genital itch and vaginal dis-
charge as indicators of genital Schistosoma haematobium morbidity in a cross-sectional study in
endemic rural Zimbabwe. Trop Med Int Health 13(12): 1509–17. https://doi.org/10.1111/j.1365-3156.
2008.02161.x PMID: 19055625
6. Hotez PJ (2013) Female genital schistosomiasis (FGS): Sub-Saharan Africa’s secret scourge of girls
and women. PLoS Speaking of Medicine. https://blogs.plos.org/speakingofmedicine/2013/05/06/
female-genital-schistosomiasis-fgs-sub-saharan-africas-secret-scourge-of-girls-and-women/. [cited 9
September 2018].
7. Kjetland EF, Ndhlovu PD, Gomo E, Mduluza T, Midzi N,Gwanzura L, et al. (2006) Association between
genital schistosomiasis and HIV in rural Zimbabwean women. AIDS 20(4): 593–600. https://doi.org/10.
1097/01.aids.0000210614.45212.0a PMID: 16470124
8. Brodish PH, Singh K (2016) Association between Schistosoma haematobium exposure and human
immunodeficiency virus infection among females in Mozambique. Am J Trop Med Hyg 94(5): 1040–4.
https://doi.org/10.4269/ajtmh.15-0652 PMID: 26976893
9. Neffo-Mbah MLN, Poolman EM Drain PK, Coffee MP, van der Werf MJ, Galvani AP (2013) HIV and
Schistosomas haematobium prevalences correlate in sub-Saharan Africa. Trop Med Int Health 18(10):
1174–9. https://doi.org/10.1111/tmi.12165 PMID: 23952297
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007025 April 4, 2019 3 / 5
10. Neffo-Mbah MLN, Poolman E, Atkins KE, Orenstein EW, Meyers LA, Townsend JP, et al. (2013) Poten-
tial cost-effectiveness of schistosomiasis treatment for reducing HIV transmission in Africa—the case of
Zimbabwean women. PLoS Negl Trop Dis 7(8): e2346. https://doi.org/10.1371/journal.pntd.0002346
PMID: 23936578
11. Neffo-Mbah NLN, Kjetland EF, Atkins KE, Poolman EM, Orenstein EW, Meyers LA, et al. (2013) Cost-
effectiveness of a community-based intervention for reducing the transmission of a Schistosoma hae-
matobium and HIV in Africa. Proc Natl Acad Sci USA 110(21):8750.
12. Merck KgaA, Schistosomiasis. https://www.emdgroup.com/en/company/responsibility/our-strategy/
health/schistosomiasis.html. [cited 9 September 2018].
13. Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Ehrlich Sachs S, Sachs JD (2006). Incorporating a
rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and
malaria. PLoS Med 3(5):e102. https://doi.org/10.1371/journal.pmed.0030102 PMID: 16435908
14. Noblick J, Skolnik R, Hotez PJ (2011) Linking global HIV/AIDS treatments with national programs for
the control and elimination of the neglected tropical diseases. PLoS Negl Trop Dis 5(7): e1022. https://
doi.org/10.1371/journal.pntd.0001022 PMID: 21814582
15. Hotez PJ, Mistry N, Rubinstein J, Sachs JD (2011) Integrating neglected tropical diseases into AIDS,
tuberculosis, and malaria control. N Engl J Med. 2011 Jun 2; 364(22):2086–9. https://doi.org/10.1056/
NEJMp1014637 PMID: 21631320
16. Hotez PJ, Fenwick A (2009) Schistosomiasis in Africa: an emerging tragedy in our new global health
decade. PLoS Negl Trop Dis 3(9): e485. https://doi.org/10.1371/journal.pntd.0000485 PMID:
19787054
17. Hotez PJ, Fenwick A, Kjetland EF (2009) Africa’s 32 cents solution for HIV/AIDS. PLoS Negl Trop Dis
3(5): e430. https://doi.org/10.1371/journal.pntd.0000430 PMID: 19479041
18. Hotez PJ, Engels D, Fenwick A, Savioli L (2010) Africa is desperate for praziquantel. Lancet 376(9740):
496–8. https://doi.org/10.1016/S0140-6736(10)60879-3 PMID: 20709217
19. Hotez P, Whitham M (2014) Helminth infections: a new global women’s health agenda. Obstet Gynecol
123(1): 155–60. PMID: 24463676
20. Christinet V, Lazdins-Helds JK, Stothard JR, Reinhard-Rupp J (2016) Female genital schistosomiasis
(FGS): from case reports to a call for concerted action against this neglected gynaecological disease.
Int J Parasitol 46(7): 395–404. https://doi.org/10.1016/j.ijpara.2016.02.006 PMID: 27063073
21. Mbabazi PS, Andan O, Fitzgerald DW, Chitsulo L, Engels D, Downs JA (2011) Examining the Relation-
ship between Urogenital Schistosomiasis and HIV Infection. PLoS Negl Trop Dis 5(12): e1396. https://
doi.org/10.1371/journal.pntd.0001396 PMID: 22163056
22. Reinhard-Rupp J, Klohe K (2017) Developing a comprehensive response for treatment of children
under 6 years of age with schistosomiasis: research and development of a pediatric formulation of
praziquantel. Infect Dis Poverty 6(1):122. https://doi.org/10.1186/s40249-017-0336-9 PMID:
28768535
23. Bustinduy AL, Friedman JF, Kjetland EF, Ezeamama AE, Kabatereine NB, Sothard JR, et al. (2016)
Expanding praziquantel (PZQ) access beyond mass drug administration programs: paving a way for-
ward for a pediatric PZQ formulation for schistosomiasis. PLoS Negl Trop Dis 10; 9: e0004946.
24. Bustinduy AL, Stothard JR, Friedman JF (2017) Paediatric and maternal schistosomiasis: shifting the
paradigms. Br Med Bull 123(1): 115–25. https://doi.org/10.1093/bmb/ldx028 PMID: 28910994
25. Norseth HM, Ndhlouvu PD, Kleppa E, Randrianasolo BS, Jourdan PM, Roald B, et al. (2014) The colpo-
scopic atlas of schistosomiasis in the lower female genital tract based on studies in Malawi, Zimbabwe,
Madagascar, and South Africa. PLoS Negl Trop Dis 8(11): e3229. https://doi.org/10.1371/journal.pntd.
0003229 PMID: 25412334
26. Ramarokoto CE, Kildemoes AO, Randrianasolo BS, Ravoniarimbinina P, Ravaoalimalala VE,
Leutscher P, et al. (2014) Eosinophil granule proteins ECP and EPX as markers for a potential early-
stage inflammatory lesion in female genital schistosomiasis (FGS). PLoS Negl Trop Dis 8(7): e2974.
https://doi.org/10.1371/journal.pntd.0002974 PMID: 25033206
27. Holmen SD, Kleppa E, Lillebo K, Pillay P, van Lieshout L, Taylor M, et al. (2015) The first step toward
diagnosing female genital schistosomiasis by computer image group. Am J Trop Med Hyg 93(1): 80–6.
28. Holmen SD, Kjetland EF, Taylor M, Kleppa E, Lellebo K, Gundersen SG, et al. (2015) Colourimetric
image analysis as a diagnostic tool in female genital schistosomiasis. Med Eng Phys 37(3): 309–14.
PMID: 25630808
29. Holmen S, Galappaththi-Arachchige HN, Kleppa E, Pillay P, Naicker T, Taylor M, et al. (2016) Charac-
teristics of blood vessels in female genital schistosomiasis: paving the way for objective diagnostics at
the point of care. PLoS Negl Trop Dis 10(4): e0004628. https://doi.org/10.1371/journal.pntd.0004628
PMID: 27073857
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007025 April 4, 2019 4 / 5
30. Hsieh MH, Le L (2017) Diagnosing urogenital schistosomiasis: dealing with diminishing returns. Trends
Parasitol 33(5): 378–87. https://doi.org/10.1016/j.pt.2016.12.009 PMID: 28094201
31. Galappaththi-Arachchige HN, Holmen S, Koukournari A, Kleppa E, Pillay P, Sebitloane M, et al. (2018)
Evaluating diagnostic indicators of urogenital Schistosoma haematobium infection in young women: a
cross sectional study in rural South Africa. PLoS ONE 13(2): e0191459. https://doi.org/10.1371/
journal.pone.0191459 PMID: 29451887
32. Richardson ML, Fu CL, Pennington LF, Honeycutt JD, Odegaard JI, Hsieh YJ, Hammam O, Conti SL,
Hsieh MH (2014) A new mouse model for female genital schistosomiasis. PLoS Negl Trop Dis 8(5):
e2825. https://doi.org/10.1371/journal.pntd.0002825 PMID: 24786606
33. Brindley PJ, Hotez PJ (2013) Break out: urogenital schistosomiasis and Schistosoma haematobium in
the post-genomic era 7(3): e1961.
34. Hotez PJ (2017) The poverty-related neglected diseases: why basic research matters. PLoS Biol
15(11): e2004186. https://doi.org/10.1371/journal.pbio.2004186 PMID: 29121043
35. Siddappa NB, Hemashettar G, Shanmuganathan V, Semenya AA, Sweeney ED, Paul KS, et al. (2011)
Schistosoma mansoni enhances host susceptibility to mucosal but not intravenous challenge by R5
Clade C SHIV. PLoS Negl Trop Dis 5(8): e1270. https://doi.org/10.1371/journal.pntd.0001270 PMID:
21829749
36. Hotez Peter J., Bottazzi Maria Elena, Bethony Jeffrey and Diemert David D. Advancing the Develop-
ment of a Human Schistosomiasis Vaccine Trends in Parasitology, 2019-02-01, Volume 35, Issue 2,
Pages 104–108, PMID: 30455112
37. Yirenya-Tawiah DR, Ackumey MM, Bosompem KM (2016) Knowledge and awareness of genital
involvement and reproductive health consequences of urogenital schistosomiasis in endemic communi-
ties in Ghana: a cross-sectional study. Reprod Health 13(1): 117. https://doi.org/10.1186/s12978-016-
0238-5 PMID: 27655032
38. Friedman JF, Olveda RM, Mirochnick MH, Bustinduy AL, Elliott AM (2018) Praziquantel for the treat-
ment of schistosomiasis during human pregnancy. Bull World Health Organ 96(1):59–65. https://doi.
org/10.2471/BLT.17.198879 PMID: 29403101
39. UNAIDS fact sheet World AIDS day 2018: 2017 Global HIV statistics. http://www.unaids.org/sites/
default/files/media_asset/UNAIDS_FactSheet_en.pdf. [cited 30 November 2018].
40. UNAIDS Joint United Nations Programme on HIV/AIDS. HIV Prevention 2020 Road Map. 2017. http://
www.unaids.org/sites/default/files/media_asset/hiv-prevention-2020-road-map_en.pdf. [cited 26 Sep-
tember 2018].
41. BRIGHT Research. Female Genital Schistosomiasis at an HIV Conference. https://brightresearch.org/
fgs-at-an-hiv-conference/. [cited 26 September 2018].
42. UNAIDS Joint United Nations Programme on HIV/AIDS. The need for a holistic approach to women and
HIV. Feature Stories. March 16, 2018. http://www.unaids.org/en/resources/presscentre/featurestories/
2018/march/20180316_holistic-approach-to-women-and-hiv. [cited 26 September 2018].
43. World Health Organization (2017) Schistosomiasis and soil-transmitted helminthiases: number of peo-
ple treated in 2016. Weekly Epidemiol Rec 8 December 92(49): 749–60.
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007025 April 4, 2019 5 / 5
